Skip to content

The Use of Extended Platelet Rich Fibrin in Lateral Sinus Augmentation

Extended Platelet Rich Fibrin in Lateral Maxillary Sinus Lifting With Simultaneous Implant Placement.

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06626776
Enrollment
30
Registered
2024-10-04
Start date
2024-10-01
Completion date
2025-10-01
Last updated
2024-10-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sinus Lift Augmentation

Brief summary

thirty implants will be inserted in patients seeking implantation of their lost posterior maxillary teeth (premolar and molars) with limited bone height below the floor of the maxillary sinus, secondary to sinus pneumatization. The patients will be selected from those attending the outpatient clinic of the Oral & Maxillofacial Surgery Department, Faculty of Dentistry, Mansoura University. 1. Clinical Evaluation • Implant stability 2. Radiographic Evaluation Vertical bone gain (VBG)

Interventions

PROCEDURElateral sinus lift with using allograft and collagen membrane

sinus floor elevation with placing allograft and collagen membrane

sinus floor elevation with placing eprf

Sponsors

Mansoura University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
20 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* Patent ostium of maxillary sinus. * Patient with missing one or more posterior maxillary teeth. * Residual bone height of 3-6 mm, measured from the crest of alveolar ridge to the floor of the maxillary sinus at the planned implant site. * A ridge width at the site of implantation of \<5mm. * Platelets of normal range. * Good oral hygiene. * Patients in the age frame between 20 years and 60 years old. * No gender preface in selection of the patients. * A minimum crown height space of 8 mm.

Exclusion criteria

* Active sinusitis, cyst, tumors or root tips at the planned surgical site. * Patients with systemic diseases that contra-indicate the surgical procedure such as uncontrolled diabetes mellitus, bleeding disorders, serious osseous disorders, and mental disorders. * Heavy smoking and alcoholism. * Parafunctional habits such as bruxism and clenching. * Signs of acute infection or pus discharge. * Disturbed occlusion.

Design outcomes

Primary

MeasureTime frameDescription
implant stability9 monthsthe stability of the implants will be evaluated by RFA with the Osstell Mentor device.
Vertical bone height6 monthsvertical bone height will be measured as the distance from the alveolar crest to the new sinus floor at the middle of the implant

Countries

Egypt

Contacts

Primary Contactammar samman
dr.3mmar@std.mans.edu.eg+201558990325

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026